Bank of Nova Scotia cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 27,180 shares of the company’s stock after selling 2,349 shares during the period. Bank of Nova Scotia’s holdings in IDEXX Laboratories were worth $4,388,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. D.A. Davidson & CO. raised its stake in IDEXX Laboratories by 160.4% during the 2nd quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock valued at $100,000 after acquiring an additional 385 shares during the last quarter. Sun Life Financial INC raised its stake in IDEXX Laboratories by 9,085.7% during the 2nd quarter. Sun Life Financial INC now owns 643 shares of the company’s stock valued at $104,000 after acquiring an additional 636 shares during the last quarter. Capital Advisors Ltd. LLC purchased a new stake in IDEXX Laboratories during the 2nd quarter valued at approximately $128,000. Global X Management Co. LLC raised its stake in IDEXX Laboratories by 44.6% during the 1st quarter. Global X Management Co. LLC now owns 1,047 shares of the company’s stock valued at $162,000 after acquiring an additional 323 shares during the last quarter. Finally, Flagship Harbor Advisors LLC purchased a new stake in IDEXX Laboratories during the 1st quarter valued at approximately $200,000. 87.58% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at 158.55 on Tuesday. The firm’s 50-day moving average price is $156.99 and its 200 day moving average price is $160.01. IDEXX Laboratories, Inc. has a 52-week low of $102.45 and a 52-week high of $173.01. The firm has a market cap of $13.84 billion, a PE ratio of 54.54 and a beta of 0.48.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, August 1st. The company reported $0.95 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.10. IDEXX Laboratories had a net margin of 14.13% and a negative return on equity of 473.46%. The firm had revenue of $508.90 million for the quarter, compared to analysts’ expectations of $502.44 million. During the same quarter last year, the company posted $0.74 earnings per share. IDEXX Laboratories’s revenue was up 9.1% on a year-over-year basis. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post $3.18 earnings per share for the current year.

WARNING: This piece of content was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/17/bank-of-nova-scotia-has-4-39-million-holdings-in-idexx-laboratories-inc-idxx.html.

In other news, Chairman Jonathan W. Ayers sold 58,000 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $155.00, for a total transaction of $8,990,000.00. Following the sale, the chairman now owns 1,043,034 shares of the company’s stock, valued at $161,670,270. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Rebecca M. Henderson sold 5,156 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $153.29, for a total value of $790,363.24. Following the sale, the director now directly owns 17,274 shares in the company, valued at approximately $2,647,931.46. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 151,734 shares of company stock worth $23,436,626. Corporate insiders own 2.77% of the company’s stock.

IDXX has been the subject of several analyst reports. BidaskClub raised IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 23rd. Stifel Nicolaus reaffirmed a “buy” rating and set a $185.00 price objective on shares of IDEXX Laboratories in a research note on Friday, July 14th. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $186.00 price objective for the company in a research note on Wednesday, July 19th. CL King raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price objective for the company in a research note on Friday, July 28th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $180.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, August 22nd. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. IDEXX Laboratories presently has an average rating of “Hold” and an average price target of $174.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Stock Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related stocks with our FREE daily email newsletter.